M3MEX:2413N 86 ROE % is 7.17% as of Mar. 2026, which is 62% below its 10-year median of 19.09. GuruFocus rates MEX:2413N with a GF Score™ of 86/100 and a GF Value™ of MXN261.79. The stock has 3 warning signs investors should review. Among 628 Healthcare Providers & Services companies, M3 ranks better than 70.38% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. M3's annualized net income for the quarter that ended in Mar. 2026 was MXN3,386 Mil. M3's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was MXN47,260 Mil. Therefore, M3's annualized ROE % for the quarter that ended in Mar. 2026 was 7.17%.
The historical rank and industry rank for M3's ROE % or its related term are showing as below:
MEX:2413N'
s ROE % Range Over the Past 10 Years
Min: 11.09 Med: 19.09 Max: 27.9
Current: 12.49
During the past 13 years, M3's highest ROE % was 27.90%. The lowest was 11.09%. And the median was 19.09%.
MEX:2413N's ROE % is ranked better than 70.38% of 628
companies
in the Healthcare Providers & Services industry
Industry Median: 5.72
vs MEX:2413N: 12.49
M3 (MEX:2413N) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
M3 ROE % Related Terms
M3 ROE % Historical Data
* Premium members only.
The historical data trend for M3's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, M3's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
M3 ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, M3's ROE % distribution charts can be found below:
* The bar in red indicates where M3's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
M3 (MEX:2413N) has a ROE % of 7.17% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on M3 and its competitors. This is 62% below median its historical median of 19.09. Over the past decade, M3's ROE % has ranged from 11.09 to 27.90. According to the industry distribution chart, M3 ranks #186 out of 628 companies in the Healthcare Providers & Services industry, placing it in the top 29.6%.
Is M3's ROE % too high?
M3's current ROE % of 7.17% is 62% below median its 10-year median of 19.09. Over the past 10 years, this metric has ranged from a low of 11.09 to a high of 27.90. The Healthcare Providers & Services industry median ROE % is 5.72. M3's value of 7.17% is 25.3% above this industry median. Based on the distribution chart, M3 ranks #186 out of 628 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, M3 has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does M3's ROE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, M3 ranks #186 out of 628 companies for ROE %. This puts M3 in the upper half of its industry. The industry median ROE % is 5.72. M3's value of 7.17% is 25.3% above this benchmark. Historically, M3's own ROE % has ranged from 11.09 to 27.90 over the past decade. While the company's 10-year median is 19.09 vs. the industry median of 5.72, M3 has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.72, based on 628 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. M3's current ROE % of 7.17% is 25.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on M3 and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. M3's current ROE % is 7.17%, which is 62% below median its own 10-year median of 19.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is M3 stock overvalued right now?
M3 (MEX:2413N) has a current ROE % of 7.17%. The stock's GF Value™ is MXN261.79, compared to a current price of MXN183.50 — trading 29.9% below its estimated fair value. The current ROE % is 7.17%, which is 62% below median its 10-year median of 19.09 and 25.3% above the Healthcare Providers & Services industry median of 5.72. M3's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For M3 (MEX:2413N), the current ROE % is 7.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is M3 (MEX:2413N) Overvalued in 2026?
Based on GuruFocus' analysis, M3 stock appears to be undervalued.
The current stock price of MXN183.50 is trading 29.9% below its estimated GF Value™ of MXN261.79.
Key valuation signals for MEX:2413N:
ROE %: 7.17% (62% below median its 10-year median of 19.09)
GF Value™: MXN261.79 vs. price of MXN183.50 (29.9% below fair value)
Industry Position: 25.3% above the Healthcare Providers & Services median (#186 of 628)
No single metric tells the full story. See the MEX:2413N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
M3 Inc is a Japan-based company engaged in providing medical-related services through internet-based platforms and real-world operations. The company operates six reportable segments: Medical Platform, Evidence Solutions, Career Solutions, Site Solutions, Patient Solutions, and Overseas. Its businesses include online marketing for medical professionals, clinical trial support, human resources services for medical professionals, operational support for medical institutions, and patient support services. The Overseas segment offers similar services internationally, including in the United States, the United Kingdom, China, South Korea, India, France, Germany, and Spain.
86GF Score
Get the complete analysis for MEX:2413N
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:2413N has been successfully added to your 
